Medicare AdvantageCoverageMedium impact
MA08.070f, Golimumab (Simponi Aria®) Intravenous (IV) Injection
Independence Blue Cross·MA · Rheumatology, Internal Medicine, Pharmacy·Pharmacy
Effective date
Aug 6, 2025
We identified it
Jun 19, 2026
Summary
This is a reissue of the MA08.070f policy for Golimumab (Simponi Aria®) IV Injection effective August 6, 2025. Without access to the full policy text, the specific changes cannot be determined; however, reissues typically indicate updates to coverage criteria, prior authorization requirements, or billing guidelines for this biologic therapy used in rheumatologic and autoimmune conditions.
Action Required
By August 6, 2025: Billing team must obtain and review the complete MA08.070f policy text from the provided URL. Identify any changes from the previous version, particularly regarding prior authorization requirements, medical necessity criteria, and covered indications. Update billing software rules, prior authorization workflows, and provider communication materials accordingly. Notify providers in affected specialties of any new requirements. Failure to implement changes may result in claim denials for Golimumab (Simponi Aria®) IV administration.